DMC Founder Professor John Fraser a co-lead on the Living Heart Project giving the gift of life
January 28, 2023
Professor John Fraser and his team have been working on The Living Heart Project for over five years in developing a technology to keep hearts viable for longer, giving a much needed boost to heart transplant recipients.
As a result of John and his team‘s efforts, they have been able to show in contrast to a normal four-to-five hour window, that it is possible to sustain a heart for as long as 8 hours and 47 minutes. One of the biggest developments in the transplant space in possibly 50 years.
More about this beautiful story can be found here.
About DMC
DMC is a clinical stage medtech company founded in Brisbane, Australia by globally recognised intensive care specialist, researcher, entrepreneur and founder Professor John Fraser AO.
DMC is developing a proprietary inhaled drug delivery platform for use in critical care emergencies. Our lead asset is an investigational inhaled epinephrine product to treat anaphylaxis.
DMC has a strong suite of intellectual property portfolio protecting both its inhaled drug delivery platform and therapeutic formulations. To date, DMC has raised more than AU$30 million from both private and public sector investors.
